Canadian company invests in Taiwanese biotechnology:
This article was originally published in Clinica
Executive Summary
The Taiwanese government has entrusted $30 million of its biotechnology development fund to MDS Capital, a Canadian venture capital firm, to invest in various industry sectors, including biomedical devices, drug delivery systems and diagnostics. The move follows a recent $580 million boost from the government to help its biotech industry increase its value to $880 million by 2005 (see Clinica No 820, p 2). The company is expected to help complete ten technology transfer projects in Taiwan within the next five years.
You may also be interested in...
Beauty Packaging Producers: July Marks Registration Deadline With PRO In Three States
Companies considered producers of single-use packaging in Oregon, Colorado and California must register with Circular Action Alliance, the leading (and currently only) producer responsibility organization, by 1 July 2024 under new state recycling laws.
Metsera Launches As New Obesity Contender Flush With $290m
Clive Meanwell, former CEO of The Medicines Company, will helm the new company, backed by ARCH and other investors. He talked to Scrip about the new venture.
Deal Watch: AbbVie Teams With MedinCell On Long-Acting Injectables
Collaboration Edition: Including deals involving Evotec/Variant, Sanofi/IGM/Nurix, ABVC/OncoX and Harmony/Bioprojet, along with tech transfer agreements and deals in brief.